Health

Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

DailyTrendDailyTrend
Apr 22, 2025 - 13:00
 0  1
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Bird Flu May Be Airborne on Dairy Farms, Scientists Report

Bird Flu May Be Airborne on Dairy Farms, Scientists Report

DailyTrend Aug 4, 2025  0  0

What’s a Potato? A Nine-Million-Year-Old Tomato

What’s a Potato? A Nine-Million-Year-Old Tomato

DailyTrend Jul 31, 2025  0  0

FDA Approves Vizz (aceclidine ophthalmic solution) for the Treatment of Presbyopia

FDA Approves Vizz (aceclidine ophthalmic solution) for ...

DailyTrend Aug 4, 2025  0  0

Major Study on Transgender Youth Health Care to Begin in U.K.

Major Study on Transgender Youth Health Care to Begin i...

DailyTrend Jul 31, 2025  0  0

Top F.D.A. Official Resigns Under Pressure

Top F.D.A. Official Resigns Under Pressure

DailyTrend Jul 30, 2025  0  0

A Cancer Patient Chose Assisted Death. That Wasn’t the Last Hard Choice.

A Cancer Patient Chose Assisted Death. That Wasn’t the ...

DailyTrend Aug 3, 2025  0  0